Skip to main navigation Skip to main content

CMH : Clinical and Molecular Hepatology

OPEN ACCESS
ABOUT
BROWSE ARTICLES
FOR CONTRIBUTORS

Page Path

2
results for

"Tumor necrosis factor-alpha"

Article category

Keywords

Publication year

"Tumor necrosis factor-alpha"

Editorial

Liver fibrosis, cirrhosis, and portal hypertension

Leaky gut-derived tumor necrosis factor-α causes sarcopenia in patients with liver cirrhosis
Takumi Kawaguchi, Takuji Torimura
Clin Mol Hepatol 2022;28(2):177-180.
Published online August 26, 2021
DOI: https://doi.org/10.3350/cmh.2021.0246

Citations

Citations to this article as recorded by  Crossref logo
  • Pathogenic Mechanisms of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)-Associated Hepatocellular Carcinoma
    Toru Nakamura, Atsutaka Masuda, Dan Nakano, Keisuke Amano, Tomoya Sano, Masahito Nakano, Takumi Kawaguchi
    Cells.2025; 14(6): 428.     CrossRef
  • The Impact of Rifaximin on Hepatic Encephalopathy during Lenvatinib Therapy in Patients with Hepatocellular Carcinoma and Splenorenal Shunt
    Shigeo Shimose, Hideki Iwamoto, Takashi Niizeki, Tomotake Shirono, Etsuko Moriyama, Takumi Kawaguchi
    Internal Medicine.2025;[Epub]     CrossRef
  • Metabolic dysfunction-associated fatty liver disease is a ubiquitous latent cofactor in viral- and alcoholic-related hepatocellular carcinoma: Editorial on “Global prevalence of metabolic dysfunction-associated fatty liver disease-related hepatocellular c
    Toru Nakamura, Masahito Nakano, Tsubasa Tsutsumi, Keisuke Amano, Takumi Kawaguchi
    Clinical and Molecular Hepatology.2024; 30(4): 705.     CrossRef
  • Interaction between sarcopenia and nonalcoholic fatty liver disease
    Sae Kyung Joo, Won Kim
    Clinical and Molecular Hepatology.2023; 29(Suppl): S68.     CrossRef
  • An ultrasensitive photoelectrochemical assay for tumor necrosis factor-alpha based on hollow CdS cubes as a signal generator and NiCo2O4-Au as a signal extinguisher
    Yamin Fu, Baohuan Fan, Shenzhen Chang, Dongyu Guo, Fuxiang Wang, Qinhe Pan
    The Analyst.2023; 148(19): 4746.     CrossRef
  • Role of increased intestinal permeability in the development and progression of liver diseases
    S. N. Mekhtiyev, O. A. Mekhtiyeva, O. M. Berko, A. M. Kolodkin
    Experimental and Clinical Gastroenterology.2023; (12): 130.     CrossRef
  • 9,187 View
  • 197 Download
  • 6 Web of Science
  • Crossref
Original Article

Liver fibrosis, cirrhosis, and portal hypertension

Association between serum tumor necrosis factor-α and sarcopenia in liver cirrhosis
Ji Won Han, Da In Kim, Hee Chul Nam, U Im Chang, Jin Mo Yang, Do Seon Song
Clin Mol Hepatol 2022;28(2):219-231.
Published online July 20, 2021
DOI: https://doi.org/10.3350/cmh.2021.0082
Background/Aims
Sarcopenia is an independent prognostic factor of liver cirrhosis (LC). However, the association between LC-related systemic inflammation and sarcopenia is unclear.
Methods
Sprague-Dawley rats were treated with thioacetamide (TAA) or saline as a control. Rifaximin was administered to TAA-induced LC rats. Enzyme-linked immunosorbent assay was performed to measure inflammatory mediators in rat serum. RT-PCR was performed to measure the molecular expression in tissues. Hematoxylin and eosin (H&E) staining and immunohistochemistry were performed to investigate tissue pathology. Serum tumor necrosis factor-α levels, liver stiffness (LS), and the L3 skeletal muscle index (L3SMI) were measured in 60 patients with chronic liver disease.
Result
s: LC and sarcopenia were successfully induced by TAA. Serum TNF-α levels were increased in LC rats and correlated with myostatin expression, muscle weight, and myofiber diameter. The expression of intestinal occludin and zona occludens-1 was reduced in LC rats and associated with serum TNF-α levels and sarcopenia. In patients with LS ≥7 kPa or sarcopenia, serum TNF-α levels were significantly increased, which was also confirmed when we raised the LS cutoff to 10 kPa. The L3SMI was inversely correlated with serum TNF-α levels in patients with LS ≥7 kPa. TNF-α was reduced by rifaximin, which might have resulted in reduced expression of muscular MuRF1 and myostatin and improvements in myofiber diameters within muscle tissues.
Conclusions
These results suggest that serum TNF-α is associated with LC-related sarcopenia. Rifaximin might be effective in reducing serum TNF-α levels and improving sarcopenia in LC, but these results need to be validated in future studies.

Citations

Citations to this article as recorded by  Crossref logo
  • New nomenclature and subclassification of steatotic liver disease and loss of skeletal muscle mass: A longitudinal cohort study
    Aryoung Kim, Danbee Kang, Sung Chul Choi, Dong Hyun Sinn, Geum‐Youn Gwak
    Hepatology Research.2025; 55(3): 373.     CrossRef
  • Sarcopenia is associated with new-onset acute biliary infection within 1 year in patients with hepatitis B virus-related decompensated cirrhosis
    Shuangshuang Zhang, Tian Zhou, Mingbo Wu, Xuanxuan Xiong
    European Journal of Gastroenterology & Hepatology.2025; 37(1): 100.     CrossRef
  • Changes in serum myostatin levels among patients with type C liver cirrhosis treated with direct‐acting antivirals
    Tomoyuki Suehiro, Hideko Kozuru, Kosuke Matusmoto, Yuki Kugiyama, Yasuhide Motoyoshi, Akira Saeki, Shinya Nagaoka, Kazumi Yamasaki, Atsumasa Komori, Hiroshi Yatsuhashi
    Hepatology Research.2025; 55(5): 631.     CrossRef
  • Correlation of sarcopenia with progression of liver fibrosis in patients with metabolic dysfunction-associated steatotic liver disease: a study from two cohorts in China and the United States
    Fan Zhang, Longgen Liu, Wenjian Li
    Nutrition Journal.2025;[Epub]     CrossRef
  • Cirrhosis Promotes Cardiac Fibrosis Development by Inhibiting Notch1 in Cardiac Fibroblasts
    He Sun, Kai Song, Ze-Yu Zhou, Bin Tu, Yang Zhou, Li-Chan Lin, Zhi-Yan Liu, Zhen-Yu Liu, Ji-Ming Sha, Yan Shi, Jing-Jing Yang, Dong Lu, Jian-Yuan Zhao, Hui Tao
    JACC: Basic to Translational Science.2025; 10(5): 612.     CrossRef
  • Rifaximin-α use is associated with improved muscle mass in patients with cirrhosis
    Thomas Worland, Penelope Hey, Darren Wong, Ross Apostolov, Roseanne Kimberley Chan, Marie Sinclair, Paul Gow
    World Journal of Hepatology.2025;[Epub]     CrossRef
  • Association of sarcopenia and physical activity on the severity of metabolic dysfunction-associated steatotic liver disease among United States adults: NHANES 2017 - 2018
    Xiaodie Wei, Xiaohui Liu, Jinhan Zhao, Yang Zhang, Lixia Qiu, Jing Zhang
    Frontiers in Aging.2025;[Epub]     CrossRef
  • Steatotic liver disease is a marker of multimorbidity, not underlying cirrhosis, in older adults
    O. Oduwole, C. Ding, N. Bitar, D. Nair, S. Salter, M. Silverman, R. Allen, L. Ng Fat, E. Tsochatzis, S. Bell, G. Mehta, A. Britton
    npj Gut and Liver.2025;[Epub]     CrossRef
  • Peripheral blood inflammatory score using a cytokine multiplex assay predicts clinical outcomes in patients treated with atezolizumab-bevacizumab for unresectable HCC
    Hee Sun Cho, Soon Kyu Lee, Ji Won Han, Jung Hyun Kwon, Soon Woo Nam, Jaejun Lee, Keungmo Yang, Pil Soo Sung, Jeong Won Jang, Seung Kew Yoon, Jong Young Choi
    Frontiers in Immunology.2025;[Epub]     CrossRef
  • Rifaximin and sarcopenia in cirrhosis: Commentary on a promising but complex relationship
    Mohamed El-Kassas, Khalid AlNaamani
    World Journal of Hepatology.2025;[Epub]     CrossRef
  • Impact of low preoperative appendicular skeletal muscle mass on postoperative complications and short-term outcomes in liver transplant recipients: a propensity score-matched retrospective study
    Jing Xu, Qian Wu, Xiaofeng Xu, Feihong Weng, Tao Lv, Jian Yang, Shouping Wang, Rui Li, Chengbo Ai, Gang Xu, Lvnan Yan, Jiayin Yang
    Frontiers in Surgery.2025;[Epub]     CrossRef
  • Synergistic Impact of Sarcopenia and T2DM on Mortality in Metabolic Dysfunction‐Associated Steatotic Liver Disease (MASLD)
    Qi Zhou, Peiyan Liu, Lixiang Li, Tengfei Yin, Hao Bai, Yanqing Li
    The FASEB Journal.2025;[Epub]     CrossRef
  • Nutritional screening and assessment tools for patients with cirrhosis based on the Global Leadership Initiative on Malnutrition criteria
    Yumei He, Ling Hu, Shiyan Wu, Lu Li, Ke Zhong, Jiazhen Li, Na Liu, Xiaobin Sun, Qiong Wang, Chao Sun, Liping Wu
    Journal of Human Nutrition and Dietetics.2024; 37(2): 430.     CrossRef
  • Screening and assessment of malnutrition in patients with liver cirrhosis
    Yumei He, Zhiming Wang, Shiyan Wu, Lu Li, Jiazhen Li, Yexing Zhang, Boshi Chen, Xiaobin Sun, Chao Sun, Liping Wu
    Frontiers in Nutrition.2024;[Epub]     CrossRef
  • Bibliometrics and knowledge mapping of the pathogenesis of hepatic encephalopathy in patients with liver cirrhosis
    Shiyan Wu, Lu Li, Heng Xi, Xiaoping Wu, Yumei He, Xiaobin Sun, Liping Wu
    Heliyon.2024; 10(15): e34330.     CrossRef
  • Unraveling the mechanisms of hepatogenous diabetes and its therapeutic perspectives
    Manisha Yadav, Smriti Verma, Purnima Tiwari, Madhav Nilakanth Mugale
    Life Sciences.2024; 353: 122934.     CrossRef
  • The Interplay Between Depression, Probiotics, Diet, Immunometabolic Health, the Gut, and the Liver—A Secondary Analysis of the Pro-Demet Randomized Clinical Trial
    Oliwia Gawlik-Kotelnicka, Jakub Rogalski, Karolina H. Czarnecka-Chrebelska, Jacek Burzyński, Paulina Jakubowska, Anna Skowrońska, Dominik Strzelecki
    Nutrients.2024; 16(23): 4024.     CrossRef
  • Effects of Alnus japonica Hot Water Extract and Oregonin on Muscle Loss and Muscle Atrophy in C2C12 Murine Skeletal Muscle Cells
    Da Hyeon An, Chan Ho Lee, Yeeun Kwon, Tae Hee Kim, Eun Ji Kim, Jae In Jung, Sangil Min, Eun Ju Cheong, Sohyun Kim, Hee Kyu Kim, Sun Eun Choi
    Pharmaceuticals.2024; 17(12): 1661.     CrossRef
  • Letter regarding “Impacts of muscle mass dynamics on prognosis of outpatients with cirrhosis”
    Do Seon Song, U Im Chang, Jin Mo Yang
    Clinical and Molecular Hepatology.2023; 29(1): 165.     CrossRef
  • Interaction between sarcopenia and nonalcoholic fatty liver disease
    Sae Kyung Joo, Won Kim
    Clinical and Molecular Hepatology.2023; 29(Suppl): S68.     CrossRef
  • Sarcopenia in cirrhosis: epidemiology, diagnosis, management and prognosis
    Yi Liu, Fanpu Ji, Mindie H. Nguyen
    Current Opinion in Gastroenterology.2023; 39(3): 131.     CrossRef
  • RETRACTED: Sinapic Acid Attenuate Liver Injury by Modulating Antioxidant Activity and Inflammatory Cytokines in Thioacetamide-Induced Liver Cirrhosis in Rats
    Ahmed Jabbar, Zaenah Alamri, Mahmood Abdulla, Ahmed AlRashdi, Soran Najmaldin, Mustafa Zainel
    Biomedicines.2023; 11(5): 1447.     CrossRef
  • The Accuracy of Ultrasound Controlled Attenuation Parameter in Diagnosing Hepatic Fat Content
    Sebastiana Atzori, Yasmin Pasha, James B Maurice, Simon D Taylor-Robinson, Louise Campbell, Adrian KP Lim
    Hepatic Medicine: Evidence and Research.2023; Volume 15: 51.     CrossRef
  • Sarcopenia in cirrhosis: Prospects for therapy targeted to gut microbiota
    Roman Maslennikov, Aliya Alieva, Elena Poluektova, Yury Zharikov, Andrey Suslov, Yana Letyagina, Ekaterina Vasileva, Anna Levshina, Evgenii Kozlov, Vladimir Ivashkin
    World Journal of Gastroenterology.2023; 29(27): 4236.     CrossRef
  • Skeletal muscle fibre morphology in childhood—insights into myopenia in pediatric liver disease
    Amber Hager, Vera Mazurak, Michelle Noga, Susan M. Gilmour, Diana R. Mager
    Applied Physiology, Nutrition, and Metabolism.2023; 48(10): 730.     CrossRef
  • What Does Sarcopenia Have to Do with Nonalcoholic Fatty Liver Disease?
    Katarzyna Ferenc, Sara Jarmakiewicz-Czaja, Rafał Filip
    Life.2023; 14(1): 37.     CrossRef
  • Hematological and biochemical investigations on the effect of curcumin and Thymoquinone in male mice exposed to Thioacetamide
    Atef M. Al-Attar
    Saudi Journal of Biological Sciences.2022; 29(1): 660.     CrossRef
  • A Review of Sarcopenia Pathophysiology, Diagnosis, Treatment and Future Direction
    Myung-Rae Cho, Sungho Lee, Suk-Kyoon Song
    Journal of Korean Medical Science.2022;[Epub]     CrossRef
  • Leaky gut-derived tumor necrosis factor-α causes sarcopenia in patients with liver cirrhosis
    Takumi Kawaguchi, Takuji Torimura
    Clinical and Molecular Hepatology.2022; 28(2): 177.     CrossRef
  • 23,933 View
  • 362 Download
  • 29 Web of Science
  • Crossref